Cognitive behavior therapy (CBT) is a structured, evidence-based psychological treatment widely applied in clinical settings worldwide.It focuses on identifying and changing negative thoughts patterns and behaviors and replace them with more balanced ones, teaching practical coping strategies like mindfulness, stress management, anger management and encouraging positive behaviors that improve mood and break cycles of anxiety.

The World Health Organization estimates that 54 million people in certain country suffer from depression, and about 41 million from anxiety disorders. Taking alcohol dependence and dementia into estimates, the lifetime prevalence rate of mental health issues is 10%, approaching those observed in Western countries. 

In countries where there is a high demand but limited access to professional mental health support, AI can provide a 24/7 immediate, scalable solutions, offering CBT-based guidance to millions who might otherwise struggle to get help. Traditional CBT can be expensive, making it inaccessible for many, AI CBT offers a cost-effective alternative, reducing barriers to mental health care while maintaining evidence-based interventions.

Unlike human therapists, whose approaches and expertise may vary, AI CBT delivers structured and consistent therapy sessions based on well-researched CBT principles without the risk of human bias and emotional fatigue. With distinctive differentiation from human memory, AI CBT raw data undergoes data cleaning, to create high-quality datasets that allow AI to learn patterns while individual cases are data points. However, please do not disclose specific personal or confidential information to AI.

Different from general AIs, AI CBT therapist integrates specific guidelines, which include "American Psychiatric Association (APA) Clinical Practice Guidelines", "VA/DoD Clinical Practice Guidelines", "Clinical Practice Guidelines for Cognitive Behavioral Therapy for Psychosis (CBTp)" and "A Provider's Guide to Brief Cognitive Behavior Therapy."

AI can be an incredible first step or complementary tool in therapy for mild and moderate mental health concerns, but AI-enabled treatments should not solely determine diagnoses and treatments without appropriate medical professional oversight. For severe symptoms like prolonged insomnia (48+ hours), hallucinations, or paranoid delusions, immediate professional intervention is necessary. 

Helpline numbers: 911(US)/112(EU)/999(UK)/144(CH)/120(CN)/. 

Meet your AI CBT therapist "Deepen", downloadable on AppStore:

With the advancement of medical science, scientists have been gaining a deeper understanding of disease mechanisms and physiological processes, leading to the continuous emergence of advanced diagnostic and therapeutic techniques. To continually improve patients’ outcomes and quality of life, and to extend survival, medical scientists and pharmacologists are relentless in their pursuit of new drug development. This is particularly evident in the fields of rare diseases, cancer, and metabolic diseases, where significant investments are made.

Clinical trials are a crucial part of the new drug development and treatment method innovation process, used to assess the safety and efficacy of new drugs and therapies. For certain diseases, especially rare diseases, cancer, and refractory conditions, clinical trials may offer new options beyond existing treatments, potentially yielding better outcomes than traditional methods. Patients participating in trials typically receive closer medical monitoring and support than in standard treatments, ensuring their health and safety. Moreover, by participating in clinical trials, patients can access the latest medical information and research developments regarding their conditions. Additionally, since the drug development duration is long (averaging 8-10 years) and requires regulatory approval before market release, patients can engage with new drugs before they are available, avoiding long waiting periods. Most patients involved in new drug clinical trials can receive free trial-related medications, special examinations, and financial compensation according to the study protocol. This is particularly beneficial for many newly launched, expensive drugs (such as anticancer medications), significantly alleviating the financial burden on families.

To participate in a clinical trial, individuals must first meet the inclusion criteria, such as age, gender, diagnosed disease, comorbidities or symptoms, and treatment history. Patients also need to sign an informed consent form, indicating their understanding of the trial's purpose, procedures, and risks. Throughout the trial, participants are required to follow the study protocol for treatment and related medical assessments.

Heavy particle radiation therapy is one of the most advanced medical treatments worldwide for malignant solid tumors. It is used to treat more than a dozen types of malignant tumors, including head and neck tumors, lung cancer, liver cancer, prostate cancer, and rectal cancer, as well as oral tumors and brain tumors that cannot be surgically treated and cancer cells resistant to X-rays. 

Statistics show that patients with malignant tumors undergoing heavy particle (carbon ion) therapy have a 5-year survival rate of 80-97%. This therapy uses charged particles, such as carbon ions, to target and destroy cancer cells. Unlike traditional radiation therapy using X-rays or protons, heavy ion therapy can deliver potent radiation directly to the tumor site with greater precision, minimizing damage to surrounding healthy tissue.

Carbon ions are high LET (linear energy transfer) rays, with about 70% of the damage occurring in the Bragg peak region being DNA double-strand breaks, which cannot be repaired. This results in a stronger biological effect in killing tumors, 2 to 3 times that of photons and protons, with a relative biological effectiveness (RBE) of 2-3. When carbon ions reach the tumor site, they release almost all their energy immediately, effectively killing tumor cells without damaging the surrounding normal tissue. Since heavy particle therapy does not involve surgical incisions, the treatment process is painless and takes about 30-60 minutes.

Heavy particle radiation therapy not only requires particle accelerator nuclear facilities but also a highly experienced medical physics team and various medications. In many countries, this therapy is highly inaccessible and in the experimental stage.

Boron Neutron Capture Therapy (BNCT) is an emerging and rapidly developing precision diagnosis and treatment technology in the international field of oncology in recent years. It has been hailed by the Japanese medical community as the "fifth therapy" following surgery, traditional radiation therapy, anti-cancer drugs, and immunotherapy. BNCT has shown outstanding clinical advantages in treating recurrent, invasive, and locally metastatic tumors, and has proven its significant and reliable efficacy in various solid tumors such as recurrent head and neck cancer, malignant brain tumors, melanoma, osteosarcoma, and breast cancer, with over a thousand clinical cases globally.

The principle of BNCT is to first inject a targeted molecular drug carrying 10B (a stable, non-radioactive natural isotope) into the body. Due to the selectivity of the targeted drug, 10B accumulates specifically in tumor tissues. A low-energy, directionally controlled epithermal neutron beam is then used to irradiate the tumor area. Upon irradiation, the 10B in the tumor tissue is activated, triggering a boron-neutron capture reaction that emits two heavy ions: α particles and 7Li particles, each with a range of about 10 microns (roughly the size of a single cancer cell) and high linear energy transfer (LET). These heavy ions break the double-stranded DNA in cancer cells, making the tumor cells irreparably damaged and ultimately leading to their complete destruction, thus achieving the precise elimination of cancer cells at the cellular level without harming normal tissues.

BNCT eliminates the need for the traditional concepts of clinical target volume (CTV) and planning target volume (PTV) in radiation therapy, enabling dual-target precision positioning. Through the use of targeted drugs or molecular probes that carry 10B atoms, the treatment selectively accumulates in tumor cells, locking them in place for a first level of targeting. Then, by selecting the irradiation field of the neutron beam to focus on the tumor area, a second level of precise targeting is achieved.

When epithermal neutrons irradiate the tumor area, they penetrate human tissue and react with the 10B in cancer cells, resulting in the emission of α particles and 7Li heavy ions. These ions, with a range of only 10 microns—the size of a single cancer cell—are extremely lethal, far surpassing traditional photon and proton therapy, earning BNCT the nickname "cell scalpel." The physical nature of BNCT’s damage can effectively avoid the drug resistance concerns associated with chemotherapy and immunotherapy.

The full course of BNCT treatment only requires 1-2 irradiation sessions, far fewer than existing radiation therapies. Compared to other particle radiation therapies, BNCT boasts stronger biological effects, requires less equipment space, can treat a greater number of patients per year, and has higher potential for widespread use and development.

Currently, the most advanced BNCT drug, BPA, can be applied to head and neck cancer, melanoma, osteosarcoma, brain and CNS tumors, and breast cancer. It is particularly suitable for treating cancers that have infiltrated, spread, or metastasized, and cannot be treated by X-rays, protons, heavy ions, or surgery. BNCT therapy is not available in most countries.

Surgical procedures are a fundamental pillar in the treatment of tumors, organ transplants, and severe cardiovascular diseases, significantly affecting patient outcomes, quality of life, and survival rates. Each surgical procedure is tailored to the specific needs and the nature of the disease or organ failure of the patient, demanding a high level of knowledge, experience, and surgical skills from the surgeon.

In terms of tumor treatment, surgical intervention is often the primary treatment method for many types of cancer. It can remove the tumor and surrounding tissues, thereby significantly reducing or eliminating cancer. Surgery can help in cancer staging, which is crucial for determining the extent of the disease and formulating further treatment plans. Biopsies are often performed during surgery to confirm a cancer diagnosis. Surgery is usually combined with other treatments such as chemotherapy or radiation therapy. This multimodal approach can enhance treatment efficacy and increase survival rates.

In the field of organ transplantation, surgery is often the last resort for patients with end-stage organ failure. Organ transplant surgery significantly improves the quality of life and survival chances by replacing failing organs with healthy ones. These surgeries require highly specialized surgical techniques to ensure successful connections between the donor organ and the recipient's blood vessels and other structures. Post-surgery, patients must manage immune responses to prevent organ rejection. The surgical component is crucial for ensuring the normal functioning of the transplanted organ and the good recovery of the recipient. Transplant surgeries also involve ethical considerations regarding donor consent and organ allocation, as well as logistical challenges in coordinating donor availability and recipient readiness.

In the treatment of cardiovascular diseases, surgery is significant, especially for patients with severe conditions or poor responses to medical therapy, where medications may not effectively control symptoms. Surgical procedures can alleviate symptoms and improve quality of life by repairing or replacing damaged blood vessels or heart valves.

Certain cardiovascular diseases, such as aneurysms or coronary artery disease, may lead to severe complications, including strokes or heart attacks, if not surgically treated. Surgery can prevent these serious outcomes. For example, Coronary Artery Bypass Grafting (CABG) can provide a new pathway for blood flow to the heart, restoring normal blood supply to the myocardium, reducing angina attacks, and lowering the risk of heart attacks. Some surgeries, like heart transplants or valve replacements, can significantly extend patient life and improve survival rates.

Peptide Receptor Radionuclide Therapy (PRRT) is part of the broader concept of targeted radionuclide therapy. PRRT delivers destructive radiation to cancer cells through peptides labeled with radionuclides. These peptides can specifically bind to peptide receptors that are expressed at higher densities on tumor cell membranes compared to non-tumor tissues. Many G protein-coupled receptors fall into this category, where their overexpression is associated with numerous human malignancies.

Regulatory peptides that target G protein-coupled receptors provide a rich source of vectors, which can be chemically modified to transport radioactivity while maintaining their receptor affinity. PRRT is used to treat metastatic or inoperable cancers, particularly neuroendocrine tumors that occur in the pancreas, kidneys, small and large intestines, and stomach, through systemic or localized delivery.

PRRT therapy typically involves four outpatient treatments over eight months, administered every two months. It includes a pre-treatment intravenous infusion of amino acids for about four hours, followed by a 30-45 minute intravenous injection of Lutetium Lu 177 dotatate. In 2004, Steve Jobs received PRRT therapy in Switzerland for NETs pancreatic cancer, which extended his life by seven years. After years of clinical application, this therapy has become more affordable, although related drug development is still in the experimental phase in China.